David A. Williams, MD
Affiliations: | Boston Children's Hospital, Harvard | Boston Children's Hospital, Harvard |
Website:
http://www.williamslaboratory.org/david-a-williams-md.htmlGoogle:
"David Williams"Mean distance: 9.26 | S | N | B | C | P |
Cross-listing: Cell & Gene Therapy Tree
Children
Sign in to add traineeRodney G. Maze | grad student | 2001 | Indiana University |
Steven R. Zeldenrust | grad student | 2001 | Indiana University |
Eric T Everett | post-doc | (Neurotree) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Zhu J, Eichler F, Biffi A, et al. (2020) The Changing Face of Adrenoleukodystrophy. Endocrine Reviews |
Brendel C, Negre O, Rothe M, et al. (2020) Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy. Molecular Therapy. Methods & Clinical Development. 17: 589-600 |
Kohn DB, Booth C, Kang EM, et al. (2020) Lentiviral gene therapy for X-linked chronic granulomatous disease. Nature Medicine |
Walters MC, Locatelli F, Thrasher AJ, et al. (2020) Safety of Autologous Hematopoietic Stem Cell Transplantation with Gene Addition Therapy for Transfusion-Dependent β-Thalassemia, Sickle Cell Disease, and Cerebral Adrenoleukodystrophy Biology of Blood and Marrow Transplantation. 26: S38-S39 |
Orchard PJ, Eichler F, Duncan C, et al. (2020) Lenti-D Hematopoietic Stem Cell Gene Therapy Stabilizes Neurologic Function in Boys with Cerebral Adrenoleukodystrophy Biology of Blood and Marrow Transplantation. 26: S37-S38 |
Curran KJ, Margossian S, Kernan NA, et al. (2019) Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL. Blood |
Hu T, Chong Y, Lu S, et al. (2019) RAC1/2 activation promotes FGFR1 driven leukemogenesis in stem cell leukemia/lymphoma syndrome. Haematologica |
Wu Y, Zeng J, Roscoe BP, et al. (2019) Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nature Medicine |
Esrick EB, Achebe M, Armant M, et al. (2019) Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing Blood. 134: LBA-5-LBA-5 |
Labrosse R, Chu J, Armant M, et al. (2019) Outcome of Hematopoietic Stem Cell Gene Therapy for Wiskott-Aldrich Syndrome Blood. 134: 4629-4629 |